It is important to highlight that the BPH group exhibited elevated levels of SOX4 and fibrosis markers, including FN1, COL1A1, and α-SMA (Fig. S8G), which were significantly reduced after Met treatment. Here, SOX4 is linked to benign prostatic hyperplasia.